Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Cipla
Cantor Fitzgerald
Express Scripts
Medtronic
Accenture
UBS
Argus Health
US Department of Justice

Generated: November 12, 2018

DrugPatentWatch Database Preview

Tentative Approvals for: terbinafine hydrochloride

« Back to Dashboard

terbinafine hydrochloride Drugs with Tentative Approvals

Applicant Generic Name NDA Strength Dosage Form
Mylan terbinafine hydrochloride 077136 EQ 250MG BASE TABLET;ORAL
Gedeon Richter Usa terbinafine hydrochloride 077065 EQ 250MG BASE TABLET;ORAL
Roxane terbinafine hydrochloride 077223 EQ 250MG BASE TABLET;ORAL
Andrx Pharm terbinafine hydrochloride 076713 EQ 250MG BASE TABLET; ORAL
Applicant Generic Name NDA Strength Dosage Form

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Accenture
Merck
Boehringer Ingelheim
Harvard Business School
Healthtrust
QuintilesIMS
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.